COR-1389 is under clinical development by Corteria Pharmaceuticals and currently in Phase I for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase I drugs for Congestive Heart Failure (Heart Failure) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how COR-1389’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

COR-1389 overview

COR-1389 is under development for the treatment of right heart failure and obesity with comorbidities. The therapeutic candidate is administered through subcutaneous route. It acts by targeting corticotropin-releasing hormone receptor 2 (CRHR2).

Corteria Pharmaceuticals overview

Corteria Pharmaceuticals (Corteria) is a pharmaceuticals and healthcare company that develops medicines for the treatment of heart failure, sarcopenia and obesity subpopulations. The company’s product portfolio include COR-1167, COR-1389 and COR-ZZZ. COR-1167 is for the treatment of worsening heart failure; COR-1389 for right heart failure and COR-ZZZ targets hyponatremic acute heart failure. The company also offers CRF2 (Corticotropin-releasing hormone receptor 2), a plasma membrane receptor for the cardiovascular, renal and metabolic systems. Corteria is headquartered in Paris, Ille-de-France, France.

For a complete picture of COR-1389’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.